The complexities of diagnosing MINOCA and INOCA remain challenging. Chiara Bucciarelli-Ducci, MD and Colin Berry, MD will talk in the following webcast about the potential of MR imaging for risk assessment and prognosis in MINOCA and INOCA patients.
Case Series: Ischemia and Infarction in Patients with Non-obstructive Coronary Arteries
Robert Sykes, Colin Berry, et al.
(West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, UK & Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK)
Scientific Literature Review: CMR for the Differential Diagnosis of Non-ischemic Cardiomyopathies
Jeanette Schulz-Menger, M.D.; et al. (Charité and HELIOS Hospital Berlin-Buch, Germany)
MINOCA. Myocardial Infarction with Non-Obstructive Coronary Arteries
Edyta Blaszczyk and Jeanette Schulz-Menger
(Working Group Cardiac MRI, Experimental and Clinical Research Center, a cooperation between the Charité Medical Faculty, the Max-Delbrück Center for Molecular Medicine, and the Department of Cardiology and Nephrology, HELIOS Clinic Berlin Buch, Germany)
Role of CMR in Non-ischemic Cardiomyopathies
Jan Gröschel, Jeanette Schulz-Menger, et al.
(Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine and HELIOS Hospital Berlin-Buch, Department of Cardiology and Nephrology, Medical University Berlin, Charité Campus Buch, Berlin, Germany)
SCMR 2021 Edition
This SCMR edition of MAGNETOM Flash provides an overview regarding the emerging role of CMR with more stratified approaches to common clinical cardiology challenges. Better stratification by underlying mechanistic markers – both imaging and blood based – will be the central ingredients to making the next advances in prevention, early detection and treatment of many cardiovascular conditions. CMR and the non-invasive window that it provides into myocardial pathology, without the need for myocardial biopsy, will undoubtedly be a central player in both better diagnosis management of individual patients as well as advances in the field through coordinated stratification and targeting of novel therapies in more efficient and powerful trials.